The Team
Robert Feldman
Dr Feldman has an invaluable combination of business, medical and research experience spanning two decades. A qualified medical practitioner, he obtained his medical degree in London, his PhD in the Netherlands, has worked at Harvard Medical School and held clinical and academic positions at Imperial College, London. Dr Feldman is a successful serial life science entrepreneur, having founded the UK vaccine company Microscience and antimicrobial company Vmax. He later went on to become CEO of hepatitis C therapeutic company, RioTech before establishing the European operations for the New York based company Paramount Biosciences, LLC. As Entrepreneur in Residence for Imperial Innovations, London, Dr Feldman also co-founded the spin-out company, Indigix. In 2010, he moved to New Zealand as Executive Director of Pacific Channel and subsequently founded his own life science consulting company, Line 5.

During his extensive and varied career, Dr Feldman has developed a breadth of medical, research and commercial expertise encompassing therapeutics, devices and diagnostics. He has also gained a deep understanding of business and product development, fundraising, venture and governance. During Dr Feldman’s time in the UK and New Zealand, he has engaged in business development activities globally, including concluding successful licensing deals in Europe, USA, Australia, Russia, South Korea and New Zealand.
Andy Herbert
Andy Herbert has worked in the biotechnology industry internationally for more than 30 years. He has a detailed knowledge of pharmaceutical manufacturing, GMP, process and product development. He specializes in helping companies through the challenges of developing products and processes that employ biotechnologies.

After receiving a doctorate in biochemical engineering sponsored by Unilever, he worked for five years in process development in ICI’s industrial fermentation and biochemicals division in the UK. He moved to Canada in 1989 and spent nine years with Sanofi-Pasteur, ultimately taking responsibility for all vaccine development in Canada. He was part of teams that developed and licensed a highly effective acellular pertussis vaccine and the human cancer vaccine ImmuCyst® (for the treatment of superficial bladder cancer). In 1998 he founded a biopharmaceutical engineering consulting company in Toronto and over the next eight years built a team which has assisted more than 30 different biotechnology client companies in Canada, USA, Mexico, Cuba and Argentina.

After moving to New Zealand in 2005 he took a role as General Manager Operations with ICPbio Ltd., leaving the firm in 2007 to set up as a consultant to biotechnology companies. He works with a range of New Zealand and overseas companies including those developing pharmaceuticals, nutraceuticals, food ingredients, new processing technologies and services. Andy was a board member of NZBIO for five years and chairman for two. He sits on the board of The Bioprocessing Network, a focus group for bioprocessing technologies in Australia. His professional memberships include Biotech NZ, ISPE and PDA.
Andy Hollings
Andy is a Massey University graduate, with almost 20 years’ experience in the biotechnology industry. He has worked in roles as varied as sport science, drug development, manufacturing and bioprocess development in both New Zealand and the UK.

Andy worked for Polybatics, the developer of CVCs biobead technology, for 4.5 years. He has hands on experience with the biobeads both in the analytical and the processing side. During his time at Polybatics he was responsible for development of new analytical methods and implemented improvements to the biobead purification process.
Tara Creaven-Capasso
With over 28 years’ experience working in the US, Europe, Australia, Japan and China, Tara specializes in providing Regulatory Affairs, Quality Assurance and Compliance services to the Biotechnology, Pharmaceutical and Medical Device sectors. Highlights include but are not limited to: product development leading to 70+ product approvals, regulatory strategy development; regulatory submission preparation; quality system establishment; GXP compliance; successful FDA inspections (including preparation and gap analysis), evaluation and risk assessment of products; non-clinical and clinical research protocol design and development; evaluation of field complaints and medical device reporting; quality, regulatory and clinical system compliance support including expedited programs, particularly in the FDA environment, or combinations of the above, from late discovery through late clinical trial and approval phases.

Tara is a subject matter experts with the Regulatory Affairs Professionals Society (RAPS), and actively participates in industry groups and meetings including but not limited to the Society of Quality Assurance (SQA) and the Society of Public Responsibility in Medicine and Research (PRIM&R). She is also an Invited speaker at national and international venues as well as an invited educator to industry and academic institutions on topics relating to product development, regulatory strategy and affairs, regulatory sciences, quality and compliance with respect to US FDA and international regulations.
Helen Teale
Helen Teale is a skilled clinical R&D, regulatory and study start-up specialist with broad therapeutic knowledge and over 20 years’ international experience of pharma, CRO, Site Management Organisations and biotechnology. Helen started her clinical research career working for two of the major UK pharmaceutical companies before being head hunted by SmithKline, to run their first pivotal study in Asia. Based in Singapore from 1996, Helen developed and managed one of the first and subsequently largest, CRO clinical teams in Asia. Reporting directly to the Board of Directors, Helen was actively involved in the recruitment of key clinical staff in Singapore, China, Thailand and Malaysia. In 2005, Helen moved to Auckland and founded Cameron Healthcare Ltd., specialising in clinical trials across New Zealand and Australia, and offering a full consultancy service for national and international bio-pharma and device companies.

During her international career, Helen has gained extensive experience of clinical operations, primary and secondary health sectors, project management, line management, medical industry personnel development and business development. She was on the board of NZACRes from 2008 to 2009 and has recently been asked to represent the clinical research community’s incentive to reduce barriers associated with the regulatory process in NZ. Helen has also been endorsed by the RNZCGP to provide Continuous Medical Education and Continuous Professional Development training in Good Clinical Practice (GCP) guidelines.

Today, Helen specialises in the project management and staffing of clinical trials (Phase I-IV) in Australia and New Zealand and frequently provides business development facilitation for universities and for major Phase I-III research units. In addition to her work with Life Science New Zealand, she continues to take an active role as Director and Owner of Cameron Healthcare Ltd.
Jeff Douglas
Jeff is managing director of New Zealand’s largest pharmaceutical company, Douglas Pharmaceuticals. Jeff has worked for the family owned company, Douglas Pharmaceuticals, for the past 40 years. During this time he has held roles in marketing and export and is currently managing director. The company employs 760 staff and has manufacturing facilities in Auckland and Fiji plus development laboratories in Philadelphia, USA. He is patron of the West Auckland Hospice, Trustee of the West Auckland Trusts Stadium, and President of the Bay of Islands Swordfish Club.
Robert Feldman
See above.
Andy Herbert
See above.
Stephen Strother
Professor, Department of Medical Biophysics, University of Toronto. He received BSc and MSc degrees in physics and mathematics from Auckland University, New Zealand followed by a PhD in Electrical Engineering from McGill University, Montreal, Canada (1986) with the help of a Rotary International Fellowship from New Zealand. After a fellowship at Memorial Sloan Kettering Cancer Center, New York, USA, in 1989 he joined the VA Medical Center, Minneapolis as a neuroimaging Physicist, and Assistant Professor of Radiology at the University of Minnesota. In 2004 he moved to Toronto, Canada as a senior scientist at the Rotman Research Institute, Baycrest, and Professor of Medical Biophysics at the University of Toronto. His research interests include neuro-informatics and data science for neuroimaging and big clinical data sets. In Canada he is a senior investigator in the Canadian Open Neuroscience Platform, and on the executives of the multi-center Ontario neurodegeneration ( and national depression ( research programs. Internationally he has represented Canada on the Council for Training, Science and Infrastructure at the Neuroscience standards organisation, INCF (, and is a past chairman of the international Neuroinformatics Standards Committee, at the National Institutes of Health, USA . In 2012 he cofounded ADMdx, Inc. in Chicago, USA, a medical analysis and diagnostics company, and he sits on the board of the not-for-profit InDoc Research, a medical informatics company in Toronto, Canada.
Kip Marks
Kip Marks (BE Mech) is a semi-retired engineer with a history of product and plant design in a number of different industries. In 1990 he founded a company which exports over 90% of its products, designed and manufactured in NZ. He now has investments in software and medicinal products and is pleased to support CVC as an opportunity to contribute to NZ’s defence against the Covid-19 virus.